3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
234
Neoplasms
206
Carcinoma, Non-Small-Cell Lung
100
Colorectal Neoplasms
98
Prostatic Neoplasms
93
Lung Neoplasms
78
Multiple Myeloma
53
Melanoma
51
Pancreatic Neoplasms
50
Head and Neck Neoplasms
49
Neoplasm Metastasis
47
Leukemia, Myeloid, Acute
43
Carcinoma, Hepatocellular
43
Ovarian Neoplasms
39
Brain Neoplasms
39
Squamous Cell Carcinoma of Head and Neck
36
Recurrence
35
Glioblastoma
33
Uterine Cervical Neoplasms
32
Sarcoma
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Glioma
29
Lymphoma, Non-Hodgkin
28
Lymphoma
27
Colonic Neoplasms
27
Stomach Neoplasms
26
Carcinoma, Renal Cell
26
Lymphoma, Follicular
25
Esophageal Neoplasms
24
Rectal Neoplasms
23
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
90 days
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA